June 5, 2018 / 12:41 PM / 6 months ago

AbbVie's rheumatoid arthritis drug succeeds in late-stage study

June 5 (Reuters) - Abbvie Inc said on Tuesday its experimental drug upadacitinib met the main goals of a late-stage study in patients with moderate-to-severe rheumatoid arthritis.

The drug is being tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below